Navigation Links
FDA Issues Complete Response Letter for Low Dose Oral Contraceptive
Date:1/27/2010

luding statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored healthcare systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... SAN ANTONIO , April 28, 2015 /PRNewswire/ ... that the U.S. Patent and Trademark Office has ... GenSpera,s intellectual property portfolio claiming numerous compositions for ... Prostate Specific Antigen (PSA).  GenSpera ... specific peptides with a powerful cytotoxin isolated from ...
(Date:4/28/2015)... 2015 /CNW/ - The group representing the living victims of ... a two-hour meeting with Health Canada officials in a ... Canada announced a $180 million support package for Thalidomide ... after the Health Canada announcement and five months after ... victims, the group representing Canada,s ...
(Date:4/28/2015)... April 28, 2015 Anteo Technologies is ... new tools developed with their patented Mix&Go™ Activation ... methods, helping to improve medical devices and in-vitro ... Increasingly complex multifactorial diagnosis of cancer and ... It is restricted to measure only a ...
Breaking Medicine Technology:GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 3
... Md., May 23, 2011 The healthcare and computing ... the healthcare industry has been adopting new technologies allowing ... medical devices strive to meet these requirements of the ... (near field frequency) chips in medical devices for communication ...
... Olympus Biotech, an Olympus Corporation company, today ... of president of Olympus Biotech Corporation. In his new ... business and focus on expanding opportunities for the emerging ... member of the Olympus Biotech Board of Directors. ...
Cached Medicine Technology:Your Wireless Healthcare Provided By PulseOximetersPlus 2Olympus Biotech Names Oliver Burckhardt to President North America 2
(Date:4/28/2015)... WUHAN, China (PRWEB) April 28, 2015 ... five major municipalities in China that will partner with ... to reduce smoking in a nation that produces more ... the world. , The project, China Tobacco Control Partnership-Tobacco ... whose leaders have shown willingness to support tobacco control ...
(Date:4/28/2015)... The popular all-natural supplement brand, Liporidex, ... newly launched L-Style Revolution Program™, and collectively the members ... just two short months. The customized weight loss ... for men and women of all health and fitness ... weight maintenance goals faster than traditional methods. , “We ...
(Date:4/28/2015)... Kansas City, Missouri (PRWEB) April 28, 2015 ... organized by the American Museum of Natural History, will ... in spring 2016, supported by sponsorship from Saint Luke’s ... in New York City, Toronto, Granada and Milan, this ... dialogue about science and technology. , “Saint Luke’s ...
(Date:4/28/2015)... 28, 2015 New and more ... more of manufacturers, payers, pharmacists and patients. Now ... journal, is partnering with the National Association of ... dedicated solely to this developing field to better ... growing need. , “This partnership creates a powerful ...
(Date:4/28/2015)... A first-in-human prostate cancer study ... and Biology showed initial safety, biodistribution, and dosimetry ... small-molecule PSMA inhibitor. The imaging biomarker has been ... by study co-author, Martin G. Pomper, MD, PhD. ... demonstrated a number of important findings. The ...
Breaking Medicine News(10 mins):Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:Saint Luke's Health System to sponsor Brain: The Inside Story exhibition at Museum at Prairiefire 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3
... by the Centre for Addiction and Mental Health (CAMH) shows ... in changing drinking behaviours and offers a significant public health ... the study published in Addiction found that problem ... alcohol consumption by 30% - or six to seven drinks ...
... Benefits of Intermittent Androgen Suppression Therapy in the Treatment ... is the title of an article by P-A. Abrahamsson ... the official journal of the European Association of Urology. ... tolerability of intermittent androgen deprivation (IAD) and assess its ...
... function in prostate cancer patients receiving external beam radiation ... treatment but then stabilizes and does not continuously decline ... the January 1 issue of the International Journal ... American Society for Radiation Oncology (ASTRO). Prostate cancer ...
... Jan. 5, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... variety of pertinent career topics impacting science and engineering ... 3 p.m. Eastern Time, the free webinar will feature ...
... Staying in a multi-bed hospital room dramatically increases the ... have discovered. A new study led by infectious diseases ... serious infections like C. difficile ( Clostridium difficile ... "If you,re in a two, three or four-bedded room, ...
... CA, January 5, 2010 As the US population becomes ... become an equal, if not greater, contributor to the burden ... smoking. In an article published in the February 2010 issue ... from Columbia University and The City College of New York ...
Cached Medicine News:Health News:Technology new gateway into treatment for problem alcohol users: Study 2Health News:Intermittent androgen deprivation at least as effective as continuous androgen deprivation 2Health News:Sexual function does not continuously decline after radiation therapy treatments for prostate cancer 2Health News:ACS Webinar features tips for using a chemistry degree in finding career opportunities 2Health News:Sharing a hospital room increases risk of 'super bugs' 2Health News:Obesity now poses as great a threat to quality of life as smoking 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: